TANIA, CLAUDIA RIKKA (2019) OPTIMASI PRIMER DAN IDENTIFIKASI VARIASI GENETIK CYP2C9 UNTUK MENGETAHUI RESPON PASIEN TERHADAP OBAT WARFARIN. Masters thesis, UNIVERSITAS MA CHUNG.
|
Text
04 611510006_Abstrak.pdf Download (74kB) | Preview |
|
|
Text
09 611510006_Bab 1.pdf Download (24kB) | Preview |
|
|
Text
10 611510006_Bab 2.pdf Download (263kB) | Preview |
|
![[img]](http://repository.machung.ac.id/style/images/fileicons/text.png) |
Text
11 611510006_Bab 3.pdf Restricted to Registered users only Download (100kB) |
|
|
Text
12 611510006_Bab 4.pdf Restricted to Registered users only Download (1MB) |
|
|
Text
13 611510006_Bab 5.pdf Download (10kB) | Preview |
|
|
Text
14 611510006_Daftar Pustaka.pdf Download (47kB) | Preview |
Abstract
Warfarin is one of the oral anticoagulant drugs used to treat or prevent thrombotic diseases (myocardial infarction, ischemic stroke, venus thrombosis, heart valve replecement and atrial fibrillation). In the pharmacokinetics, warfarin
has a short therapeutic index that causes quite serious side effects that are bleeding. One of the mechanisms of warfarin is associated with vitamin K work in the process
of wound healing. Warfarin in his work is influenced by the enzyme cytochrome, namely CYP4F2 and CYP2C9 (*2,*3). Restriction Fragment Length Polymorphism (RFLP) analysis is one of the first techniques widely used to detect variations at the DNA sequence level. Detection of RFLP is based on the possibility to compare the
profile of the bands produced after cutting with retraction enzymes against the target DNA / from different individuals. This research aims to determine the genetic variation of CYP2C9 in cardiac patients who will get warfarin therapy in the Stone Baptist Hospital, so that can be done dose adjustment so as to prevent the occurrence of side effects of bleeding Using the PCR-RFLP method. The results of
the electrophoresis indicate that CYP2C9*2 and CYP2C9*3 are obtained from DNA isolation in the size of BP. The process of PCR-RFLP CYP2C9*2 is done using annealing temperature of 59oC, DNA templates 0.5 μl and firepole 0.4 μl.
Whereas in CYP2C9*3 used the temperature of 63oC with the DNA handlebars 1 μl and firepole as much as 4 μl. As a result, each sample of CYP2C9*2 reads below 100 BP is still on a straight line that signifies no cuts with the addition of Ava II's retrial enzyme which should have been read at 29 BP and 50 bp. Whereas in each of CYP2C9*3 samples read below 100 BP but none sample that gives the results of
two lines that indicate no cuts with the addition of Ava II's retrial enzyme that should have been read at 15 BP and 35 BP. Based on the results of studies that have been carried out on blood samples of Baptist Batu Hospital patients it is known that there is no genetic variation in CYP2C9* 2 or CYP2C9* 3, so no dose adjustment is needed for warfarin therapy.Keywords: CYP2C9, PCR-RFLP, Warfarin
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | TUGAS AKHIR |
| Subjects: | R Medicine > R Medicine (General) |
| Divisions: | Fakultas Ilmu Kesehatan > S1 Farmasi |
| Depositing User: | Surya |
| Date Deposited: | 13 Feb 2025 02:45 |
| Last Modified: | 13 Feb 2025 02:45 |
| URI: | http://repository.machung.ac.id/id/eprint/834 |
Actions (login required)
 |
View Item |
